TomoTherapy

TomoTherapy, founded in 1997 and headquartered in the United States, specializes in developing and selling advanced radiation therapy solutions for a wide range of cancers. The company's flagship product, the TomoTherapy® platform, integrates CT imaging with conformal radiation therapy to deliver precise and speedy radiation treatments while minimizing exposure to healthy tissue. Their Hi·Art® treatment system has successfully delivered over three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions. TomoTherapy also offers the TomoHD™ treatment system, designed for treating a broader patient population with a single device, and the TomoMobile™ relocatable radiation therapy solution, aimed at enhancing access to state-of-the-art cancer care. The company's last investment was a Venture Round investment on 30 November 2000, led by Advantage Capital Partners. With more than 350 systems in use across 24 countries worldwide, TomoTherapy has established a significant global presence in the Biotechnology, Health Care, and Manufacturing industries. As a publicly traded company on the NASDAQ Global Select Market under the symbol TOMO, TomoTherapy continues to drive innovation in the field of radiation therapy. To learn more about TomoTherapy, visit their website at TomoTherapy.com.